Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes

被引:13
|
作者
Inciardi, Riccardo M. [1 ,2 ,3 ]
Giugliano, Robert P. [4 ]
Park, Jeong-Gun [4 ]
Nordio, Francesco [4 ]
Ruff, Christian T. [4 ]
Chen, Cathy [5 ]
Lanz, Hans -Joachim [6 ]
Antman, Elliott M. [4 ]
Braunwald, Eugene [4 ]
Solomon, Scott D. [1 ,7 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Cardiovasc Div, Boston, MA USA
[2] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlth, Div Cardiol, Brescia, Italy
[3] Univ Brescia, ASST Spedali Civili Brescia, Brescia, Italy
[4] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp,Dept Med, Boston, MA USA
[5] Daiichi Sankyo Pharm Dev, Cardiovasc Metab & Renal Dis Therapeut Area, Global Clin Dev, Basking Ridge, NJ USA
[6] Daiichi Sankyo Europe GmbH, Munich, Germany
[7] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
atrial fibrillation; heart failure; major bleeding; stroke/systemic embolic events; PRESERVED EJECTION FRACTION; CATHETER ABLATION; MORTALITY; INSIGHTS; WARFARIN; PREVALENCE; EDOXABAN; EPIDEMIOLOGY; METAANALYSIS; EFFICACY;
D O I
10.1016/j.jacep.2022.11.032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND The risks of heart failure (HF) events compared with stroke/systemic embolic events (SEE) or major bleeding (MB) in heart failure with reduced ejection fraction (HFrEF) vs heart failure with preserved ejection fraction (HFpEF) in a large atrial fibrillation (AF) population have not been well-studied. OBJECTIVES This study sought to assess HF outcomes, according to HF history and HF phenotypes (HFrEF vs HFpEF), and compare these events with SEE and MB, among patients with AF. METHODS We analyzed patients enrolled in the ENGAGE-AF TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48) trial. Cumulative incidence of heart failure hospitalization (HHF) or HF death was assessed and compared with the rates of fatal and nonfatal stroke/ SEE and MB over a median follow-up of 2.8 years. RESULTS Overall, 12,124 (57.4%) had a history of HF (37.7% HFrEF, 40.1% HFpEF, 22.1% with unknown ejection fraction). The rate per 100 person-years (py) of HHF or HF death (4.95; 95% CI: 4.70-5.20) was higher than of fatal and nonfatal stroke/SEE (1.77; 95% CI: 1.63-1.92) and MB (2.66; 95% CI: 2.47-2.86) among patients with HF history. HFrEF patients experienced a higher rate of HHF or HF death compared with HFpEF patients (7.15 vs 3.65; P < 0.001), while the rates of fatal and nonfatal stroke/SEE and MB were similar by HF phenotype. Patients with HF history had a higher rate of mortality after a HHF (1.29; 95% CI: 1.17-1.42) than after a stroke/SEE (0.69; 95% CI: 0.60-0.78) or after MB (0.61; 95% CI: 0.53-0.70). Overall, patients with nonparoxysmal AF had a higher rate of HF and stroke/SEE events regardless of HF history. CONCLUSIONS Patients with AF and HF, regardless of ejection fraction, are at a higher risk of HF events with higher subsequent mortality rates than of stroke/ SEE or MB. While HFrEF is associated with a higher risk of HF events than HFpEF, the risk of stroke/SEE and MB is similar between HFrEF and HFpEF. ( J Am Coll Cardiol EP 2023;9:569-580) (c) 2023 by the American College of Cardiology Foundation.
引用
收藏
页码:569 / 580
页数:12
相关论文
共 50 条
  • [31] Biomarkers in Atrial Fibrillation and Heart Failure
    Oikonomou, Evangelos
    Zografos, Theodoros
    Papamikroulis, Georgios-Angelos
    Siasos, Gerasimos
    Vogiatzi, Georgia
    Theofilis, Panagiotis
    Briasoulis, Alexandros
    Papaioannou, Spyridon
    Vavuranakis, Manolis
    Gennimata, Vasiliki
    Tousoulis, Dimitris
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (05) : 873 - 887
  • [32] Management of atrial fibrillation in heart failure
    Gamez Lopez, A. L.
    Bonilla Palomas, J. L.
    Lopez Ibanez, M. C.
    Moreno Conde, M.
    Pimentel Quezada, Y.
    Villar Raez, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 563 - 564
  • [33] Atrial Fibrillation Ablation and Heart Failure
    Man, Jonathan
    Marchlinski, Francis E.
    CURRENT CARDIOLOGY REPORTS, 2012, 14 (05) : 571 - 576
  • [35] Comorbidity of atrial fibrillation and heart failure
    Liang-Han Ling
    Peter M. Kistler
    Jonathan M. Kalman
    Richard J. Schilling
    Ross J. Hunter
    Nature Reviews Cardiology, 2016, 13 : 131 - 147
  • [36] Treatment of Atrial Fibrillation in Heart Failure
    Le Heuzey, Jean-Yves
    Marijon, Eloi
    Otmani, Akli
    Lepillier, Antoine
    Waintraub, Xavier
    Lavergne, Thomas
    Pornin, Maurice
    THERAPIE, 2009, 64 (02): : 115 - 119
  • [37] Atrial fibrillation and congestive heart failure
    Bourke, T.
    Boyle, N. G.
    MINERVA MEDICA, 2009, 100 (02) : 137 - 143
  • [38] Atrial fibrillation and heart failure in the elderly
    Pedram Kazemian
    Gavin Oudit
    Bodh I. Jugdutt
    Heart Failure Reviews, 2012, 17 : 597 - 613
  • [39] Predictors of atrial fibrillation in heart failure
    Ruiz Olgado, MJMaria Jose
    Gonzalez Sarmiento, R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 362 - 362
  • [40] Atrial fibrillation in patients with heart failure
    Hynes, BJ
    Luck, JC
    Wolbrette, DL
    Bhatta, L
    Khan, M
    Samii, S
    Naccarelli, GV
    CURRENT OPINION IN CARDIOLOGY, 2003, 18 (01) : 32 - 38